News
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.
WFRV Local 5 on MSN1d
New tariffs could raise prices of Ozempic, WegovySome of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback